Wednesday, Oct 07th

Last update03:28:32 AM GMT

You are here News Health FDA staff note deaths in Pfizer bone drug study

FDA staff note deaths in Pfizer bone drug study

E-mail Print PDF
A higher percentage of patients treated with an experimental Pfizer Inc drug for osteoporosis died during a clinical trial compared with a placebo, U.S. drug reviewers said in an analysis released on Thursday.

The higher proportion of deaths through five years was statistically significant only for the lowest dose of the drug called Fablyn, said Food and Drug Administration reviewers. More patients given Fablyn, which was co-developed with Ligand Pharmaceuticals Inc, also developed blood clots.


Most Recent Related Stories...

FDA approves new treatment for advanced lung cancer

new lung cancer drugThe Food and Drug Administration approved a new drug for patients with advanced non-small cell lung...

Scientists share Nobel Prize for medicine for anti-parasite drugs

Nobel in medicineThree scientists from Japan, China and Ireland whose discoveries led to the development of potent new...

California governor signs assisted suicide bill

California assisted suicide bill signedCalifornia will become the fifth state to allow terminally ill patients to legally end their lives...

Doctors Without Borders leaves Kunduz after 'inexcusable' air strike

DWBInternational medical charity Doctors Without Borders (MSF) said Sunday it has withdrawn staff from the embattled...
America's # 1 Enemy
Tee Shirt
& Help Support!
TVNL Tee Shirt
Conserve our Planet
& Help Support!
Get your 9/11 & Media
Deception Dollars
& Help Support!
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!